Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors

FASEB Journal

Volumn 25, Issue 6, 2011, Pages 2040-2048

  Delluc, Stephanie ^a   Ravot, Gilles ^a   Maillere, Bernard ^b  

^a Parc Georges Besse   (France)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

Humanization; Immunogenicity; Naive

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; ETANERCEPT; HLA DR ANTIGEN; INFLIXIMAB; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ALLOTYPE; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; DONOR; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TISSUE DONORS;

MURINAE;

EID: 79957906233     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-173872     Document Type: Article

References (54)

1. Arstila, T. P., Casrouge, A., Baron, V., Even, J., Kanellopoulos, J., and Kourilsky, P. (1999) A direct estimate of the human αβ T cell receptor diversity. Science 286, 958-961
2. + T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27, 203-213
3. Duda, P. W., Krieger, J. I., Schmied, M. C., Balentine, C., and Hafler, D. A. (2000) Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. 165, 7300-7307
4. Zhang, Y., Renkvist, N., Sun, Z., Schuler-Thurner, B., Glaichenhaus, N., Schuler, G., Boon, T., van der Bruggen, P., and Colau, D. (2005) A polyclonal anti-vaccine CD4 T-cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35, 1066-1075 (Pubitemid 40542213)
5. + T cells in cancer-free individuals. Clin. Immunol. 117, 161-167
6. + T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J. Exp. Med. 206, 1525-1534
7. Klein, L., Hinterberger, M., Wirnsberger, G., and Kyewski, B. (2009) Antigen presentation in the thymus for positive selection and central tolerance induction. Nat. Rev. Immunol. 9, 833-844
8. Kappler, J. W., Roehm, N., and Marrack, P. (1987) T cell tolerance by clonal elimination in the thymus. Cell 49, 273-280
9. Cibotti, R., Kanellopoulos, J. M., Cabaniols, J. P., Halle-Panenko, O., Kosmatopoulos, K., Sercarz, E., and Kourilsky, P. (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. U. S. A. 89, 416-420
10. Haribhai, D., Engle, D., Meyer, M., Donermeyer, D., White, J. M., and Williams, C. B. (2003) A threshold for central T cell tolerance to an inducible serum protein. J. Immunol. 170, 3007-3014
11. Bogen, B., Dembic, Z., and Weiss, S. (1993) Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J. 12, 357-363 (Pubitemid 23042415)
12. Loirat, D., Mancini-Bourgine, M., Abastado, J. P., and Michel, M. L. (2003) HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int. Immunol. 15, 1125-1136
13. Yule, T. D., Basten, A., and Allen, P. M. (1993) Hen egg-white lysozyme-specific T cells elicited in hen egg-white lysozyme-transgenic mice retain an imprint of self-tolerance. J. Immunol. 151, 3057-3069
14. Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., Bakkus, M., Thielemans, K., Arnout, J., Peerlinck, K., Gilles, J. G., Vermylen, J., and Saint-Remy, J. M. (1998) Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92, 496-506
15. Antonelli, G., Giannelli, G., Currenti, M., Simeoni, E., Del Vecchio, S., Maggi, F., Pistello, M., Roffi, L., Pastore, G., Chemello, L., and Dianzani, F. (1996) Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin. Exp. Immunol. 104, 384-387 (Pubitemid 26000364)
16. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. J. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241-3248
17. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469-475 (Pubitemid 34441737)
18. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., and George, A. J. (2010) The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325-338
19. Pijpe, J., van Imhoff, G. W., Spijkervet, F. K., Roodenburg, J. L., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G., and Bootsma, H. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740-2750 (Pubitemid 41369102)
20. Smith, K. G., Jones, R. B., Burns, S. M., and Jayne, D. R. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970-2982
21. Tanaka, Y., Yamamoto, K., Takeuchi, T., Nishimoto, N., Miyasaka, N., Sumida, T., Shima, Y., Takada, K., Matsumoto, I., Saito, K., and Koike, T. (2007) A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17, 191-197 (Pubitemid 46929903)
22. Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., and Kromminga, A. (2009) Immunogenicity of rituximab in patients with severe pemphigus. Clin. Immunol. 132, 334-341
23. Thurlings, R. M., Teng, O., Vos, K., Gerlag, D. M., Aarden, L., Stapel, S. O., van Laar, J. M., Tak, P. P., and Wolbink, G. J. (2009) Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 69, 409-412
24. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens. G., D. H., Carbonez, A., and Rutgeerts, P. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (Pubitemid 36204954)
25. Hanauer, S. B., Wagner, C. L., Bala, M., Mayer, L., Travers, S., Diamond, R. H., Olson, A., Bao, W., and Rutgeerts, P. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 542-553 (Pubitemid 38834038)
26. Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., and Saxne, T. (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54, 3782-3789 (Pubitemid 44955878)
27. Radstake, T. R., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H., Enevold, C., van Riel, P. L., and Bendtzen, K. (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1739-1745
28. De Vries, M. K., Wolbink, G. J., Stapel, S. O., de Vrieze, H., van Denderen, J. C., Dijkmans, B. A., Aarden, L. A., and van der Horst-Bruinsma, I. E. (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 66, 1252-1254
29. Denton, C. P., Engelhart, M., Tvede, N., Wilson, H., Khan, K., Shiwen, X., Carreira, P. E., Diaz Gonzalez, F., Black, C. M., and van den Hoogen, F. H. (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 68, 1433-1439
30. Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Jr., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., and Adelman, D. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (Pubitemid 32119100)
31. Van Walle, I., Gansemans, Y., Parren, P. W., Stas, P., and Lasters, I. (2007) Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7, 405-418 (Pubitemid 46383483)
32. Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A., Tak, P. P., and Wolbink, G. J. (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (Pubitemid 46999794)
33. Bender, N. K., Heilig, C. E., Droll, B., Wohlgemuth, J., Armbruster, F. P., and Heilig, B. (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27, 269-274 (Pubitemid 46088257)
34. Barbosa, M. D., Vielmetter, J., Chu, S., Smith, D. D., and Jacinto, J. (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity. Clin. Immunol. 118, 42-50 (Pubitemid 43012045)
35. Jacquemin, M., Vantomme, V., Buhot, C., Lavend'homme, R., Burny, W., Demotte, N., Chaux, P., Peerlinck, K., Vermylen, J., Maillere, B., Van Der Bruggen, P., and Saint-Remy, J. M. (2003) CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101, 1351-1358
36. Yeung, V. P., Chang, J., Miller, J., Barnett, C., Stickler, M., and Harding, F. A. (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172, 6658-6665
37. Bray, G. L., Kroner, B. L., Arkin, S., Aledort, L. W., Hilgartner, M. W., Eyster, M. E., Ragni, M. V., and Goedert, J. J. (1993) Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am. J. Hematol. 42, 375-379 (Pubitemid 23104809)
38. Delluc, S., Ravot, G., and Maillere, B. (2010) Quantification of the pre-existing CD4 T cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 116, 4542-4545
39. Boulain, J. C., and Menez, A. (1982) Neurotoxin-specific immunoglobulins accelerate dissociation of the neurotoxin-acetylcholine receptor complex. Science 217, 732-733 (Pubitemid 12049573)
40. Schmitt, N., Morita, R., Bourdery, L., Bentebibel, S. E., Zurawski, S. M., Banchereau, J., and Ueno, H. (2009) Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 31, 158-169
41. Colombani, J. (1993) HLA: Fonctions Immunitaires et Applications Médicales, John Libbey Eurotext, Paris
42. De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., and Martin, W. (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "tregitopes." Blood 112, 3303-3311
43. Dore, R. K., Mathews, S., Schechtman, J., Surbeck, W., Mandel, D., Patel, A., Zhou, L., and Peloso, P. (2007) The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25, 40-46 (Pubitemid 46477484)
44. Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., and Jahreis, A. (2007) Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol. 143, 719-726 (Pubitemid 46955730)
45. De Vries, M. K., van der Horst-Bruinsma, I. E., Nurmohamed, M. T., Aarden, L. A., Stapel, S. O., Peters, M. J., van Denderen, J. C., Dijkmans, B. A., and Wolbink, G. J. (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68, 531-535
46. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833
47. Piro, L. D., White, C. A., Grillo-Lopez, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., Kolitz, J. E., and Jain, V. (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10, 655-661 (Pubitemid 29342370)
48. Peng, A., Gaitonde, P., Kosloski, M. P., Miclea, R. D., Varma, P., and Balu-Iyer, S. V. (2009) Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice. J. Pharm. Sci. 98, 4480-4484
49. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S., and Strominger, J. L. (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178, 27-47
50. Lippolis, J. D., White, F. M., Marto, J. A., Luckey, C. J., Bullock, T. N., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2002) Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J. Immunol. 169, 5089-5097
51. Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., and Sanz, I. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (Pubitemid 39062719)
52. Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., de Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., and Dijkmans, B. (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54, 711-715
53. Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., Li, J., and Pollack, P. F. (2007) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232-1239
54. Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., and Gottlieb, A. B. (2003) Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022